Inhibikase Therapeutics, Inc. (IKT) has a negative trailing P/E of -3.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 4.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -28.62%, forward earnings yield 20.58%.
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -122.8 | 0.00 | -57.11 | 79.79 | - |
| 2017 | -234.3 | 4.89 | -70.91 | 49.58 | - |
| 2018 | -36.9 | -0.07 | -101.98 | 19.63 | - |
| 2019 | -17.9 | -0.17 | -22.76 | 91.01 | - |
| 2020 | -24.4 | 0.50 | 7.09 | 99.29 | - |
| 2021 | -1.8 | -0.01 | 0.70 | 8.63 | - |
| 2022 | -0.7 | 0.05 | 0.60 | 102.12 | - |
| 2023 | -0.4 | 0.02 | 0.62 | 26.00 | - |
| 2024 | -8.2 | 0.12 | 2.38 | 0.00 | - |
| 2025 | -4.2 | 0.07 | 1.17 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.48 | $967.39K | $-628.74K | -65% |
| 2017 | $-0.25 | $2.06M | $-436.08K | -21.2% |
| 2018 | $-1.61 | $4.04M | $-2.15M | -53.3% |
| 2019 | $-3.34 | $1.12M | $-5.75M | -511.9% |
| 2020 | $-1.72 | $698.47K | $-2.88M | -411.9% |
| 2021 | $-4.88 | $3.1M | $-14.81M | -477.5% |
| 2022 | $-4.26 | $123.44K | $-17.91M | -14505.2% |
| 2023 | $-3.57 | $260.5K | $-19.03M | -7304.8% |
| 2024 | $-1.16 | $0.00 | $-27.52M | - |
| 2025 | $-0.49 | $0.00 | $-48.26M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.38 | $-0.53 – $-0.17 | $500K | $500K – $500K | 5 |
| 2027 | $-0.45 | $-0.45 – $-0.45 | $1M | $1M – $1M | 4 |
| 2028 | $-0.37 | $-0.44 – $-0.27 | $36.74M | $36.74M – $36.74M | 4 |
| 2029 | $-0.39 | $-0.39 – $-0.39 | $109.96M | $109.96M – $109.96M | 2 |
| 2030 | $-0.16 | $-0.16 – $-0.16 | $28.33M | $28.33M – $28.33M | 2 |
